2025 Spring Exhibitors and Sponsors

AbbVie is driving the pursuit of improved mental health. Over the last 30 years, the company’s scientists and clinicians have worked to tackle the complexity of mental illness and today offer a portfolio of medicines and a pipeline of innovation that spans depression, anxiety, bipolar disorder, and schizophrenia. To learn more about AbbVie’s work to support individuals throughout their mental health journey, please visit www.abbvie.com or follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. 

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

A leader in addiction medicine, Behavioral Health Group (BHG) is the largest network of Joint Commission-accredited outpatient opioid treatment centers in the United States. We offer comprehensive, personalized evidence-based medical and behavioral therapies for people with opioid use disorder. With 114 locations in 22 states, ~2,000 employees serve more than 43,000 patients every day. Learn more at BHGrecovery.com.

Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow. Therapeutic areas include: Oncology, Immunology, Neuroscience, Cardiopulmonary and Specialty ophthalmology.

To learn more, visit our website https://www.jnj.com/

Circular Genomics is a pioneering precision psychiatric and neurologic medicine biotechnology company, using advanced technology and proprietary data to uncover insights for personalized care. We focus on circular RNA biomarkers to diagnose and treat psychiatric and neurological disorders, empowering individuals to better understand their mental and brain health and find optimal treatments.

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (formerly Twitter), and Facebook.

As the global leader in generic medicine, nearly 200 million people across six continents take one of our products every day. We also invest hundreds of millions of dollars every year to help our scientists develop specialty and biopharmaceutical treatments that aim to increase access and improve patients’ health. Since Teva’s establishment in 1901 in Jerusalem, our leadership in healthcare has been marked by tenacity, entrepreneurial spirit, and an aspiration to improve people's lives. This defines how we do business and motivates thousands of Teva employees all over the world, every single day.

Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized. Visit www.alkermes.com to learn more. 

Proudly endorsed by APA (American Psychiatric Association), American Professional Agency is the liability insurance of choice for Psychiatrists. We offer several premium discounts, 24/7 access to risk management professionals, risk management education courses, and offer robust cyber coverage as an endorsement. It’s fast and easy to switch. Call 800.421.6694 or click our logo for more information.

Axsome is developing therapies for CNS conditions with limited treatment options. By creating treatments with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing therapeutic approaches that meaningfully improve the lives of patients and provide additional options for physicians.

Collegium Pharmaceutical is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have a portfolio of medications in pain management and ADHD.

Teva Medical strives to provide to access educational, clinical/scientific information and resources designed to advance the exchange of information regarding Teva's medicines and therapeutic areas with the medical community.

Proudly endorsed by APA (American Psychiatric Association), American Professional Agency is the liability insurance of choice for Psychiatrists. We offer several premium discounts, 24/7 access to risk management professionals, risk management education courses, and offer robust cyber coverage as an endorsement. It’s fast and easy to switch. Call 800.421.6694 or click our logo for more information.